# Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients

> **NCT07366658** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 9 (estimated)

## Conditions studied

- SCLC, Extensive Stage
- Neuroendocrine Tumors

## Interventions

- **BIOLOGICAL:** Biological/Vaccine: NK Cell Therapy Product Derived from Induced Pluripotent Stem Cells (iPSCs) Engineered with Anti-DLL3 CAR Construct, Followed by Differentiation and Expansion

## Key facts

- **NCT ID:** NCT07366658
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2026-10-20
- **Final completion:** 2027-01-20
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- Neukio Biotherapeutics (Shanghai) Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07366658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07366658, "Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07366658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*